1dvs

From Proteopedia
Revision as of 17:30, 12 November 2007 by OCA (talk | contribs) (New page: left|200px<br /> <applet load="1dvs" size="450" color="white" frame="true" align="right" spinBox="true" caption="1dvs, resolution 2.Å" /> '''CRYSTAL STRUCTURE OF ...)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
File:1dvs.gif


1dvs, resolution 2.Å

Drag the structure with the mouse to rotate

CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH RESVERATROL

OverviewOverview

The human amyloid disorders, familial amyloid polyneuropathy, familial, amyloid cardiomyopathy and senile systemic amyloidosis, are caused by, insoluble transthyretin (TTR) fibrils, which deposit in the peripheral, nerves and heart tissue. Several nonsteroidal anti-inflammatory drugs and, structurally similar compounds have been found to strongly inhibit the, formation of TTR amyloid fibrils in vitro. These include flufenamic acid, diclofenac, flurbiprofen, and resveratrol. Crystal structures of the, protein-drug complexes have been determined to allow detailed analyses of, the protein-drug interactions that stabilize the native tetrameric, conformation of TTR and inhibit the formation of amyloidogenic TTR. Using, a structure-based drug design approach ortho-trifluormethylphenyl, anthranilic acid and N-(meta-trifluoromethylphenyl) phenoxazine 4, 6-dicarboxylic acid have been discovered to be very potent and specific, TTR fibril formation inhibitors. This research provides a rationale for a, chemotherapeutic approach for the treatment of TTR-associated amyloid, diseases.

DiseaseDisease

Known diseases associated with this structure: Amyloid neuropathy, familial, several allelic types OMIM:[176300], Amyloidosis, senile systemic OMIM:[176300], Carpal tunnel syndrome, familial OMIM:[176300], Dystransthyretinemic hyperthyroxinemia OMIM:[176300]

About this StructureAbout this Structure

1DVS is a Single protein structure of sequence from Homo sapiens with STL as ligand. Full crystallographic information is available from OCA.

ReferenceReference

Rational design of potent human transthyretin amyloid disease inhibitors., Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, Sacchettini JC, Nat Struct Biol. 2000 Apr;7(4):312-21. PMID:10742177

Page seeded by OCA on Mon Nov 12 16:36:37 2007

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA